Tiffany Sepp is the CEO of Vanguard Clinical, Inc., an organization specializing in the execution of cinical trials for rare disease research, and the founder of the Vanguard Clinical Rare Disease Foundation. A dynamic leader in the ultra-rare and neurodegenerative disease space, Tiffany is recognized for her innovative approach to accelerating therapies for pediatric populations with high unmet need. She served as the development team leader for Zebronkysen, an individualized medicine for Amelia and Makenzie’s rare form of CLN3 Batten disease. Tiffany currently partners with multiple families and advocacy groups to advance development programs for other forms of Batten disease and rare genetic neurodegenerative conditions. Her work bridges the gap between patient urgency and clinical execution, reshaping what’s possible in rare disease drug development.